Related references
Note: Only part of the references are listed.Effectiveness and Safety of Vonoprazan versus Proton Pump Inhibitors for Second-Line Helicobacter pylori Eradication Therapy: Systematic Review and Meta-Analysis
Satoshi Shinozaki et al.
DIGESTION (2021)
A Potassium-Competitive Acid Blocker-Based Regimen as Second-Line Therapy Improves Helicobacter pylori Eradication
Haruaki Nabeta et al.
DIGESTION (2020)
A Triple-Drug Blister-Packaged Drug with Vonoprazan Improves First-Line Eradication ofHelicobacter pyloriin Elderly Patients: A Retrospective Propensity Score-Matched Cohort Study
Tsutomu Nishida et al.
DIGESTION (2020)
Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori
Takahisa Furuta et al.
DIGESTION (2020)
Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line Helicobacter pylori treatment: a multicentre randomised trial in Japan
Sho Suzuki et al.
GUT (2020)
Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis
Alexander Charles Ford et al.
GUT (2020)
Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan
Ryusuke Horie et al.
HELICOBACTER (2020)
Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer
Yu Kyung Cho et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2020)
Randomized trial of vonoprazan-based versus proton-pump inhibitor-based third-line triple therapy with sitafloxacin for Helicobacter pylori
Soichiro Sue et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Efficacy and Safety of Vonoprazan-Based versus Proton Pump Inhibitor-Based Triple Therapy for Helicobacter pylori Eradication: A Meta-Analysis of Randomized Clinical Trials
Qiu-Ju Lyu et al.
BIOMED RESEARCH INTERNATIONAL (2019)
Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication
Maho Kusunoki et al.
INTERNAL MEDICINE (2019)
Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection
Tetsuya Shinmura et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES (2019)
Vonoprazan-Based Third-Line Therapy Has a Higher Eradication Rate against Sitafloxacin-Resistant Helicobacter pylori
Yoshimasa Saito et al.
CANCERS (2019)
Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis
Kwang Jae Lee et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2019)
Current status of first- and second-line Helicobacter pylori eradication therapy in the metropolitan area: a multicenter study with a large number of patients
Hideki Mori et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2019)
Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial
Soichiro Sue et al.
HELICOBACTER (2018)
Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy
Haruhiko Ozaki et al.
DIGESTION (2018)
Systematic review with meta-analysis: Vonoprazan, a potent acid blocker, is superior to proton-pump inhibitors for eradication of clarithromycin-resistant strains of Helicobacter pylori
Min Li et al.
HELICOBACTER (2018)
Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen
Satoshi Shinozaki et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2018)
Vonoprazan-based triple therapy is non-inferior to susceptibility-guided proton pump inhibitor-based triple therapy for Helicobacter pylori eradication
Hiroki Tanabe et al.
ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2018)
Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date
Kentaro Sugano
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2018)
Second-line triple therapy in failures with vonoprazan-based triple therapy for eradication of Helicobacter pylori
Naoyoshi Mori et al.
BIOMEDICAL REPORTS (2018)
Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed
Yasumi Katayama et al.
GUT (2017)
Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report
P. Malfertheiner et al.
GUT (2017)
Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication
Yusaku Kajihara et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2017)
In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker
Hitomi Yamasaki et al.
XENOBIOTICA (2017)
Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin
Shoko Ono et al.
HELICOBACTER (2017)
Review: A Japanese population-based meta-analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion?
Shou Quan Dong et al.
HELICOBACTER (2017)
The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication
Soichiro Sue et al.
INTERNAL MEDICINE (2017)
Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection
Toshihiro Nishizawa et al.
JOURNAL OF CLINICAL BIOCHEMISTRY AND NUTRITION (2017)
Comparative study: Vonoprazan and proton pump inhibitors in Helicobacter pylori eradication therapy
Kouichi Sakurai et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin
Soichiro Sue et al.
GASTROENTEROLOGY RESEARCH AND PRACTICE (2017)
Vonoprazan-Based Regimen Is More Useful than PPI-Based One as a First-Line Helicobacter pylori Eradication: A Randomized Controlled Trial
Masafumi Maruyama et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2017)
Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature
Hiroki Tanabe et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication
Y. S. Jung et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Letter: CYP3A4/5 genotype status and outcome of vonoprazan-containing Helicobacter pylori eradication therapy in Japan
M. Sugimoto et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2017)
Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype
T. Kagami et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
The Efficacy and Tolerability of a Triple Therapy Containing a Potassium-Competitive Acid Blocker Compared With a 7-Day PPI-Based Low-Dose Clarithromycin Triple Therapy
Sho Suzuki et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2016)
A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori
Masahiro Tsujimae et al.
DIGESTION (2016)
Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance
Hiroshi Matsumoto et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
Kazunari Murakami et al.
GUT (2016)
Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice
Satoki Shichijo et al.
JOURNAL OF DIGESTIVE DISEASES (2016)
A novel potassium-competitive acid blocker improves the efficacy of clarithromycin-containing 7-day triple therapy against Helicobacter pylori
Journal of Gastrointestinal and Liver Diseases (2016)
Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori
Satoshi Shinozaki et al.
KAOHSIUNG JOURNAL OF MEDICAL SCIENCES (2016)
Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects
H. Jenkins et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2015)
Helicobacter pylori-Induced Signaling Pathways Contribute to Intestinal Metaplasia and Gastric Carcinogenesis
Soichiro Sue et al.
BIOMED RESEARCH INTERNATIONAL (2015)
A Matched Case-Control Study of a Novel Acid-Pump Antagonist and Proton-Pump Inhibitor for the Treatment of latrogenic Ulcers Caused by Endoscopic Submucosal Dissection
Yong Gil Kim et al.
GUT AND LIVER (2010)
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication
A. Villoria et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication:: a meta-analysis
M Vallve et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2002)
Current role of acid suppressants in Helicobacter pylori eradication therapy
J Labenz
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2001)
Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy - A meta-analytical approach
MP Dore et al.
DIGESTIVE DISEASES AND SCIENCES (2000)
Share Paper
